![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ACP: Pricing Transparency Can Help Squelch Drug Costs
ACP: Pricing Transparency Can Help Squelch Drug Costs
April 6, 2016
Pricing transparency is a key ingredient in bringing down prescription drug costs, according to a policy paper from the American College of Physicians.
The paper says that to achieve a meaningful reduction of drug prices, drugmakers should disclose actual material and production costs to regulators, along with the cost of developing a drug.
ACP’s report, which appeared in the March 29 edition of the Annals of Internal Medicine, also states that “rigorous price transparency standards” are needed for drugs developed using taxpayer dollars.
Upcoming Events
-
21Oct